Genocea Biosciences Inc. buy Reibach111
Summary
This prediction ended on 10.09.18 with a price of €4.32. The BUY prediction by Reibach111 for Genocea Biosciences Inc. performed very badly with a performance of -48.00%. Reibach111 has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | -5.630% | -5.765% | 8.425% | 8.571% |
iShares Nasdaq 100 | -8.559% | -13.005% | 17.297% | 28.853% |
iShares Nikkei 225® | -9.576% | -9.058% | 3.827% | 0.117% |
iShares S&P 500 | -6.631% | -7.103% | 17.407% | 31.169% |
Comments by Reibach111 for this prediction
In the thread Genocea Biosciences Inc. diskutieren
Reibach111 stimmt dem Crowdsentiment von 'Buy' zu
Reibach111 stimmt am 08.03.2018 dem Buy-Crowdsentiment mit dem Kursziel 3.0$ zu.
Stopped prediction by Reibach111 for Genocea Biosciences Inc.
Genocea Biosciences Inc.
13.03.19
03.06.19
03.06.19